Clostridium difficile exposure as an insidious source of infection in healthcare settings: An epidemiological model

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Yakob, Laith ^a   Riley, Thomas V ^b   Paterson, David L ^a   Clements, Archie C A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BACTERIAL COLONIZATION; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; CONTROLLED STUDY; DISEASE TRANSMISSION; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGICAL DATA; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HUMAN; HYGIENE; IMMUNE STATUS; INFECTIOUS DIARRHEA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MATHEMATICAL ANALYSIS; MICROFLORA; PREVALENCE; PROBABILITY; SANITATION; STOCHASTIC MODEL;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DYSENTERY; HOSPITALS; HUMANS; INCIDENCE; MASS SCREENING; MODELS, THEORETICAL; STOCHASTIC PROCESSES;

EID: 84881529136     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-376     Document Type: Article

References (62)

1. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006, 12(3):409-415. 10.3201/eid1203.051064, 3291455, 16704777.
2. Wilcox MH, Smyth ET. Incidence and impact of clostridium difficile infection in the UK, 1993-1996. J Hosp Infect 1998, 39(3):181-187. 10.1016/S0195-6701(98)90256-0, 9699137.
3. Lo Vecchio A, Zacur G. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 2012, 28:1-9. 10.1097/MOG.0b013e32834bc9a9, 22134217.
4. Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, Roberts T, Croyle K, Krystofiak S, Patel-Brown S, et al. A large outbreak of clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005, 26(3):273-280. 10.1086/502539, 15796280.
5. Ricciardi R, Rothenberger DA, Madoff RD, Baxter NN. Increasing prevalence and severity of clostridium difficile colitis in hospitalized patients in the united states. Arch Surg 2007, 142(7):624-631. 10.1001/archsurg.142.7.624, 17638799.
6. McGlone SM, Bailey RR, Zimmer SM, Popovich MJ, Tian Y, Ufberg P, Muder RR, Lee BY. The economic burden of clostridium difficile. Clin Microbiol Infect 2012, 18(3):282-289. 10.1111/j.1469-0691.2011.03571.x, 21668576.
7. Benson L, Song X, Campos J, Singh N. Changing epidemiology of clostridium difficile-associated disease in children. Infect Control Hosp Epidemiol 2007, 28(11):1233-1235. 10.1086/520732, 17926272.
8. Clements ACA, Magalhaes RJS, Tatem AJ, Paterson DL, Riley TV. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis 2010, 10(6):395-404. 10.1016/S1473-3099(10)70080-3, 20510280.
9. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. Clinical practice guidelines for clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of america (IDSA). Infect Control Hosp Epidemiol 2010, 31(5):431-455. 10.1086/651706, 20307191.
10. Curry SR, Muto CA, Schlackman JL, Pasculle AW, Shutt KA, Marsh JW, Harrison LH. Use of MLVA genotyping to determine the role of asymptomatic carriers in C. Difficile transmission. Clin Infect Dis 2013, in press.
11. Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RLP, Donskey CJ. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic clostridium difficile strains among long-term care facility residents. Clin Infect Dis 2007, 45(8):992-998. 10.1086/521854, 17879913.
12. Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired clostridium difficile-associated disease. JAMA 2005, 294(23):2989-2995. 10.1001/jama.294.23.2989, 16414946.
13. McFarland LV, Beneda HW, Clarridge JE, Raugi GJ. Implications of the changing face of clostridium difficile disease for health care practitioners. Am J Infect Control 2007, 35(4):237-253. 10.1016/j.ajic.2006.06.004, 17482995.
14. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of clostridium difficile infection. N Engl J Med 1989, 320(4):204-210. 10.1056/NEJM198901263200402, 2911306.
15. Sethi A, Al-Nassir W, Nerandzic M, Bobulsky G, Donskey C. Persistence of skin contamination and environmental shedding of clostridium difficile during and after treatment of C. Difficile infection. Infect Control Hosp Epidemiol 2010, 31(1):21-27. 10.1086/649016, 19929371.
16. Eggertson L. C. Difficile may have killed 2000 in quebec: study. Can Med Assoc J 2005, 173(9):1020-1021.
17. Starr JM, Campbell A. Mathematical modeling of clostridium difficile infection. Clin Microbiol Infect 2001, 7(8):432-437. 10.1046/j.1198-743x.2001.00291.x, 11591207.
18. Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN. Acquisition of clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 1992, 166(3):561-567. 10.1093/infdis/166.3.561, 1323621.
19. Starr JM, Campbell A, Renshaw E, Poxton IR, Gibson GJ. Spatio-temporal stochastic modelling of clostridium difficile. J Hosp Infect 2009, 71(1):49-56. 10.1016/j.jhin.2008.09.013, 19013677.
20. Loo VG, Bourgault A-M, Poirier L, Lamothe F, Michaud S, Turgeon N, Toye B, Beaudoin A, Frost EH, Gilca R, et al. Host and pathogen factors for clostridium difficile infection and colonization. N Engl J Med 2011, 365(18):1693-1703. 10.1056/NEJMoa1012413, 22047560.
21. Lanzas C, Dubberke ER, Lu Z, Reske KA, Grohn YT. Epidemiological model for clostridium difficile transmission in healthcare settings. Infect Control Hosp Epidemiol 2011, 32(6):553-561. 10.1086/660013, 3645005, 21558767.
22. Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, Kuijper EJ, Wilcox MH. The changing epidemiology of clostridium difficile infections. Clin Microbiol Rev 2010, 23(3):529-549. 10.1128/CMR.00082-09, 2901659, 20610822.
23. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med 2008, 359(18):1932-1940. 10.1056/NEJMra0707500, 18971494.
24. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009, 7(7):526-536. 10.1038/nrmicro2164, 19528959.
25. Best EL, Fawley WN, Parnell P, Wilcox MH. The potential for airborne dispersal of clostridium difficile from symptomatic patients. Clin Infect Dis 2010, 50(11):1450-1457. 10.1086/652648, 20415567.
26. Roberts K, Smith CF, Snelling AM, Kerr KG, Banfield KR, Sleigh PA, Beggs CB. Aerial dissemination of clostridium difficile spores. BMC Infect Dis 2008, 8:7-7. 10.1186/1471-2334-8-7, 2245947, 18218089.
27. Kyne L, Merry C, O'Connell B, Kelly A, Keane C, O'Neill D. Factors associated with prolonged symptoms and severe disease due to clostridium difficile. Age Ageing 1999, 28(2):107-113. 10.1093/ageing/28.2.107, 10350405.
28. Bignardi GE. Risk factors for clostridium difficile infection. J Hosp Infect 1998, 40(1):1-15. 10.1016/S0195-6701(98)90019-6, 9777516.
29. Johnson S. Recurrent clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009, 58(6):403-410. 10.1016/j.jinf.2009.03.010, 19394704.
30. OECD Health at a Glance 2011: OECD Indicators 2011, OECD Publishing, OECD.
31. MacDougall C, Polk R. Variability in rates of Use of antibacterials among 130 US hospitals and risk-adjustment models for interhospital comparison. Infect Control Hosp Epidemiol 2008, 29:203-211. 10.1086/528810, 18257689.
32. Polk R, Fox C, Mahoney A, Letcavage JCM. Measurement of adult antibacterial drug Use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis 2007, 44:664-670. 10.1086/511640, 17278056.
33. Rafii F, Sutherland J, Cerniglia C. Effects of treatment with antimicrobial agents on the human colonic microflora. Ther Clin Risk Manag 2008, 4:1343-1358. 2643114, 19337440.
34. Keeling M, Rohani P. Modeling infectious diseases in humans and animals 2007, Princeton, NJ: Princeton University Press.
35. Johnson S, Clabots CR, Linn FV, Olson MM, Peterson LR, Gerding DN. Nosocomial clostridium difficile colonisation and disease. Lancet 1990, 336(8707):97-9100. 10.1016/0140-6736(90)91605-A, 1975332.
36. McFarland LV. Update on the changing epidemiology of clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol 2008, 5(1):40-48. 10.1038/ncpgasthep1029, 18174906.
37. Leffler DA, Lamont JT. Treatment of clostridium difficile-associated disease. Gastroenterology 2009, 136(6):1899-1912. 10.1053/j.gastro.2008.12.070, 19457418.
38. Bartlett JG. Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis 1984, 6(suppl 1):S235-S241.
39. McBryde ES, Pettitt AN, McElwain DLS. A stochastic mathematical model of methicillin resistant staphylococcus aureus transmission in an intensive care unit: predicting the impact of interventions. J Theor Biol 2007, 245(3):470-481. 10.1016/j.jtbi.2006.11.008, 17188714.
40. Gillespie DT. Exact stochastic simulation of coupled chemical reactions. J Phys Chem 1977, 81(25):2340-2361.
41. Muto CA, Blank MK, Marsh JW, Vergis EN, O'Leary MM, Shutt KA, Pasculle AW, Pokrywka M, Garcia JG, Posey K, et al. Control of an outbreak of infection with the hypervirulent clostridium difficile BI strain in a university hospital using a comprehensive " bundle" approach. Clin Infect Dis 2007, 45(10):1266-1273. 10.1086/522654, 17968819.
42. Walker AS, Eyre DW, Wyllie DH, Dingle KE, Harding RM, O'Connor L, Griffiths D, Vaughan A, Finney J, Wilcox MH, et al. Characterisation of clostridium difficile hospital ward-based transmission using extensive epidemiological data and molecular typing. PLoS Med 2012, 9(2):e1001172. 10.1371/journal.pmed.1001172, 3274560, 22346738.
43. Eastwood K, Else P, Charlett A, Wilcox M. Comparison of nine commercially available clostridium difficile toxin detection assays, a real-time PCR assay for C. Difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J Clin Microbiol 2009, 47(10):3211-3217. 10.1128/JCM.01082-09, 2756932, 19710274.
44. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of clostridium difficile and serum levels of IgG antibody against toxin a. N Engl J Med 2000, 342(6):390-397. 10.1056/NEJM200002103420604, 10666429.
45. Bauer MP, Kuijper EJ, van Dissel JT. European society of clinical microbiology and infectious diseases (ESCMID): treatment guidance document for clostridium difficile infection (CDI). Clin Microbiol Infect 2009, 15(12):1067-1079. 10.1111/j.1469-0691.2009.03099.x, 19929973.
46. Khanna S, Pardi D, Aronson S, Kammer P, Orenstein R, St Sauver J, Harmsen W, Zinsmeister A. The epidemiology of community-acquired clostridium difficile infection: a population-based study. Am J Gastroenterol 2012, 107:89-95. 10.1038/ajg.2011.398, 3273904, 22108454.
47. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. Can Med Assoc J 2004, 171(1):33-38.
48. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault A-M, Nguyen T, Frenette C, Kelly M, et al. A predominantly clonal multi-institutional outbreak of clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353(23):2442-2449. 10.1056/NEJMoa051639, 16322602.
49. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995, 16:459-477. 10.1086/648363, 7594392.
50. Mayfield JL, Leet T, Miller J, Mundy LM. Environmental control to reduce transmission of clostridium difficile. Clin Infect Dis 2000, 31:995-1000. 10.1086/318149, 11049782.
51. Thomas C, Stevenson M, Williamson DJ, Riley TV. Clostridium difficile-associated diarrhea: epidemiological data from western australia associated with a modified antibiotic policy. Clin Infect Dis 2002, 35:1457-1462. 10.1086/342691, 12471563.
52. Aldeyab MA, Kearney MP, Scott MG, Aldiab MA, Alahmadi YM, Darwish Elhajji FW, Magee FA, McElnay JC. An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of clostridium difficile infection in hospital settings. J Antimicrob Chemother 2012, 67(12):2988-2996. 10.1093/jac/dks330, 22899806.
53. Jump RLPMDP, Olds DMRNP, Seifi NMS, Kypriotakis GMS, Jury LARNCNP, Peron EPP, Hirsch AAP, Drawz PEMD, Watts BMD, Bonomo RAMD, et al. Effective antimicrobial stewardship in a long-term care facility through an infectious disease consultation service: keeping a LID on antibiotic Use. Infect Control Hosp Epidemiol 2012, 33(12):1185-1192. 10.1086/668429, 23143354.
54. Nathwani D, Sneddon J, Malcolm W, Wiuff C, Patton A, Hurding S, Eastaway A, Seaton RA, Watson E, Gillies E, et al. Scottish antimicrobial prescribing group (SAPG): development and impact of the scottish national antimicrobial stewardship programme. Int J Antimicrob Agents 2011, 38(1):16-26. 10.1016/j.ijantimicag.2011.02.005, 21515030.
55. Valiquette L, Cossette B, Garant M-P, Diab H, Pépin J. Impact of a reduction in the Use of high-risk antibiotics on the course of an epidemic of clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007, 45(2):S112-S121.
56. Anderson RM, Garnett GP. Mathematical models of the transmission and control of sexually transmitted diseases. Sex Transm Dis 2000, 27:636-643. 10.1097/00007435-200011000-00012, 11099079.
57. Nowak M, Anderson R, McLean A, Wolfs T, Goudsmit J, May R. Antigenic diversity thresholds and the development of AIDS. Science 1991, 254:963-969. 10.1126/science.1683006, 1683006.
58. Yakob L, Clements ACA. A mathematical model of chikungunya dynamics and control: the major epidemic on réunion island. PLoS ONE 2013, 8(3):e57448. 10.1371/journal.pone.0057448, 3590184, 23554860.
59. Yakob L, Dunning R, Yan G. Indoor residual spray and insecticide-treated bednets for malaria control: theoretical synergisms and antagonisms. J R Soc Interface 2011, 8(59):799-806. 10.1098/rsif.2010.0537, 3104351, 21084340.
60. Yakob L, Yan G. Modeling the effects of integrating larval habitat source reduction and insecticide treated nets for malaria control. PLoS ONE 2009, 4(9):e6921. 10.1371/journal.pone.0006921, 2734167, 19742312.
61. Ferguson N, Keeling MJ, Edmunds WJ, Gani R, Brenfell BT, Anderson RM, Leach S. Planning for smallpox outbreaks. Nature 1991, 425:681-685.
62. Meyers LA. Contact network epidemiology: bond percolation applied to infectious disease prediction and control. Bull Am Math Soc 2007, 44:63-86.